Octreotide (Acetate)

Octreotide (Acetate) is a parenteral synthetic analogue of the naturally occurring hormone somatostatin. The activity of octreotide is similar to that of somatostatin. Octreotide, however, has a longer half-life, greater selectivity for inhibiting glucagon, growth hormone, and insulin release, and a lower incidence of rebound hypersecretion following discontinuation. Based on this activity, octreotide has been approved for use in controlling the symptoms associated with vasoactive intestinal peptide tumors (VIPomas; watery diarrhea) and metastatic carcinoid tumors (flushing and diarrhea). Other non-approved uses of octreotide include AIDS-associated diarrhea, esophageal varices, and pituitary tumors (i.e., acromegaly and thyrotropinomas).

Brands
SANDOSTATIN SANDOSTATIN SANDOSTATIN LAR ASTEROTIDE JINTROTIDE HATIDE HATIDE
Adult Dose
Dose: 0.05 to 0.2 mg
Single Dose: 0.12 (0.125)
Frequency: 8 hourly
Route: SC
Instructions:
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
Octreotide (Acetate) also known as octreotide. . It is of Synthetic origin and belongs to Octapeptide. It belongs to Somatostatin agonist pharmacological group on the basis of mechanism of action and also classified in Antidiarrhoeals pharmacological group.The Molecular Weight of Octreotide (Acetate) is 1019.30. Its pKa is 6.8, 9.7.
Contraindications
Octreotide (Acetate)
Effects
The severe or irreversible adverse effects of Octreotide (Acetate), which give rise to further complications include Gall stones.Octreotide (Acetate) produces potentially life-threatening effects which include Hypoglycemia, Hypoglycemia, Hypoglycemia, Hepatic dysfunction, Acute pancreatitis. which are responsible for the discontinuation of Octreotide (Acetate) therapy.The symptomatic adverse reactions produced by Octreotide (Acetate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Loose stools, Anorexia, Abdominal pain, Pain, Local pain, Local reactions, Nausea and vomiting, Tingling, Steatorrhea, Tenderness, Bloating, Stinging.
Indications
Octreotide (Acetate) is primarily indicated in conditions like Acromegaly, Adjunct in ganciclovir treatment, Carcinoid tumours, Glucagonoma, Hormone-mediated secretory diarrhea, To reduce intestinal secretions and vomiting (palliative care), Variceal bleeding, Vipoma, and can also be given in adjunctive therapy as an alternative drug of choice in Acromegaly (short-term treatment before pituitary surgery), Hormone-mediated secretory diarrhea (can be benefit in refactory cases), Symptoms associated with carcinoid tumours, To reduce intestinal secretions and vomiting.
Interactions
Octreotide (Acetate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementBromocriptine (Mesylate)Plasma concentration of Bromocriptine increased by Octreotide.CabergolineCimetidine (HCl)Cyclosporin AHuman InsulinInsulin LisproPergolidePioglitazoneVORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inj Store at room temperature or refrigerator. Do not Freeze. Protect from Sunlight. Use within 2 weeks if kept at room temperature.
Warnings
Octreotide should be used with caution in patients with kidney disease, diabetes, any other illness or any allergy. Check should be made for gallstone before prolonged therapy and at 6 to 12 months interval during treatment.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.